EP2010213A4 - Verwendung und zusammensetzungen zur behandlung von juveniler rheumatoider arthritis - Google Patents

Verwendung und zusammensetzungen zur behandlung von juveniler rheumatoider arthritis

Info

Publication number
EP2010213A4
EP2010213A4 EP07755184A EP07755184A EP2010213A4 EP 2010213 A4 EP2010213 A4 EP 2010213A4 EP 07755184 A EP07755184 A EP 07755184A EP 07755184 A EP07755184 A EP 07755184A EP 2010213 A4 EP2010213 A4 EP 2010213A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
rheumatoid arthritis
juvenile rheumatoid
juvenile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07755184A
Other languages
English (en)
French (fr)
Other versions
EP2010213A2 (de
Inventor
Edward H Giannini
John R Medich
Alberto Martini
Daniel J Lovell
Nicolino Ruperto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
Original Assignee
Abbott Biotech Ltd Bermuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotech Ltd Bermuda filed Critical Abbott Biotech Ltd Bermuda
Priority to EP13172516.0A priority Critical patent/EP2666479A3/de
Publication of EP2010213A2 publication Critical patent/EP2010213A2/de
Publication of EP2010213A4 publication Critical patent/EP2010213A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP07755184A 2006-04-10 2007-04-10 Verwendung und zusammensetzungen zur behandlung von juveniler rheumatoider arthritis Withdrawn EP2010213A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13172516.0A EP2666479A3 (de) 2006-04-10 2007-04-10 Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79090906P 2006-04-10 2006-04-10
US80977006P 2006-05-30 2006-05-30
US81548906P 2006-06-20 2006-06-20
US85837606P 2006-11-10 2006-11-10
PCT/US2007/008826 WO2007120651A2 (en) 2006-04-10 2007-04-10 Uses and compositions for treatment of juvenile rheumatoid arthritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP13172516.0A Division EP2666479A3 (de) 2006-04-10 2007-04-10 Anwendungen und Zusammensetzungen zur Behandlung von juveniler rheumatoider Arthritis

Publications (2)

Publication Number Publication Date
EP2010213A2 EP2010213A2 (de) 2009-01-07
EP2010213A4 true EP2010213A4 (de) 2010-08-11

Family

ID=38610129

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07755184A Withdrawn EP2010213A4 (de) 2006-04-10 2007-04-10 Verwendung und zusammensetzungen zur behandlung von juveniler rheumatoider arthritis

Country Status (2)

Country Link
EP (1) EP2010213A4 (de)
WO (1) WO2007120651A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY31861A (es) 2008-06-03 2010-01-05 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR20140015139A (ko) 2009-10-15 2014-02-06 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2807014A1 (en) 2010-08-03 2012-02-09 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012502A2 (en) * 2000-08-07 2002-02-14 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012502A2 (en) * 2000-08-07 2002-02-14 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BREEDVELD F C ET AL: "The efficacy and safety of Adalimunab (Humira((R))) plus Methotrexate vs. Adalimumab alone or methotrexate alone in the early treatment of rheumatoid arthritis (RA): 1-and 2-year results of the premier study", July 2005, ANNALS OF THE RHEUMATIC DISEASES, VOL. 64, NR. SUPPL. 3, PAGE(S) 60, ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY; VIENNA, AUSTRIA; JUNE 08 11, 2005, ISSN: 0003-4967, XP009132992 *
CHIKANZA IAN C: "Juvenile rheumatoid arthritis: therapeutic perspectives.", PAEDIATRIC DRUGS 2002 LNKD- PUBMED:11994038, vol. 4, no. 5, 2002, pages 335 - 348, XP009132928, ISSN: 1174-5878 *
HASHKES PHILIP J ET AL: "Medical treatment of juvenile idiopathic arthritis.", JAMA : THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 5 OCT 2005 LNKD- PUBMED:16204667, vol. 294, no. 13, 5 October 2005 (2005-10-05), pages 1671 - 1684, XP002580537, ISSN: 1538-3598 *
HORNEFF G: "Treatment of juvenile idiopathic arthritis", ZEITSCHRIFT FÜR RHEUMATOLOGIE, STEINKOPFF-VERLAG, DA LNKD- DOI:10.1007/S00393-005-0748-Y, vol. 64, no. 5, 1 June 2005 (2005-06-01), pages 317 - 326, XP019382946, ISSN: 1435-1250 *
LAHDENNE P ET AL: "Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: An open label study.", ANNALS OF THE RHEUMATIC DISEASES, vol. 62, no. 3, March 2003 (2003-03-01), pages 245 - 247, XP009132942, ISSN: 0003-4967 *
LOVELL D: "Biologic agents for the treatment of juvenile rheumatoid arthritis: Current status", PEDIATRIC DRUGS 2004 NZ LNKD- DOI:10.2165/00148581-200406030-00001, vol. 6, no. 3, 2004, pages 137 - 146, XP009132929, ISSN: 1174-5878 *
LOVELL DANIEL J ET AL: "Etanercept in children with polyarticular juvenile rheumatoid arthritis", NEW ENGLAND JOURNAL OF MEDICINE, vol. 342, no. 11, 16 March 2000 (2000-03-16), pages 763 - 769, XP002580532, ISSN: 0028-4793 *
LOVELL DANIEL J ET AL: "Preliminary data from the study of adalimumab in children with Juvenile Idiopathic Arthritis", ARTHRITIS & RHEUMATISM, vol. 50, no. Suppl. S, 1096, 2004, & 68TH ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY; SAN ANTONIO, TX, USA; OCTOBER 16 -21, 2004, pages S436 - S437, XP009132938, ISSN: 0004-3591 *
MARTINI GIORGIA ET AL: "Juvenile idiopathic arthritis: current and future treatment options.", EXPERT OPINION ON PHARMACOTHERAPY MAR 2006 LNKD- PUBMED:16503811, vol. 7, no. 4, March 2006 (2006-03-01), pages 387 - 399, XP009132927, ISSN: 1744-7666 *
WEISS J E ET AL: "Juvenile idiopathic arthritis", PEDIATRIC CLINICS OF NORTH AMERICA 200504 US LNKD- DOI:10.1016/J.PCL.2005.01.007, vol. 52, no. 2, April 2005 (2005-04-01), pages 413 - 442, XP009132933, ISSN: 0031-3955 *

Also Published As

Publication number Publication date
WO2007120651A2 (en) 2007-10-25
WO2007120651A3 (en) 2008-07-31
EP2010213A2 (de) 2009-01-07

Similar Documents

Publication Publication Date Title
EP2010214A4 (de) Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis
EP2010213A4 (de) Verwendung und zusammensetzungen zur behandlung von juveniler rheumatoider arthritis
EP2007426A4 (de) Anwendungen und zusammensetzungen zur behandlung von psoriasis-arthritis
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
PT2101766T (pt) Composições e métodos de utilização de (r)-pramipexole
IL190520A0 (en) Compositions and methods for treatment of autoimmune
IL200766A0 (en) Compositions and methods for the prevention and treatment of autoimmune conditions
IL197945A (en) Liquid Zalcogenic Preparations and Methods for their Preparation
PT2293816E (pt) Métodos para o tratamento da artrite reumatoide
ZA200900388B (en) Compositions and methods for the treatment of mucositis
IL197804A0 (en) Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
PL1816116T6 (pl) Kompozycje chemiczne i sposoby ich wytwarzania
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
EP1996218A4 (de) Verfahren und zusammensetzungen zur behandlung gastrointestinaler erkrankungen
PL2631241T3 (pl) Sposób generowania białka i jego zastosowanie
ZA200902255B (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
EP2104554A4 (de) Teilchenzusammensetzungen
PL2101766T3 (pl) Kompozycje i sposoby stosowania (R)-pramipeksolu
IL211704A0 (en) Tetracycline compounds for the treatment of rheumatoid arthritis and related methods of treatment
EP2109673A4 (de) Verfahren und vorrichtung für verstärkte protein-expression und -reinigung
IL196411A0 (en) Anti-cocaine compositions and treatment
EP2124968A4 (de) Zusammensetzungen und verfahren zur behandlung von muskelschwund
EP1912630A4 (de) Zusammensetzungen und verfahren zur verringerung von postoperativen schmerzen
GB0601950D0 (en) Compositions and methods of treating diabetes
ZA200903645B (en) Stable S-nitrosothiols, method of synthesis and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1126676

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20100713

17Q First examination report despatched

Effective date: 20110609

RAX Requested extension states of the european patent have changed

Extension state: RS

Payment date: 20081110

Extension state: HR

Payment date: 20081110

Extension state: MK

Payment date: 20081110

Extension state: BA

Payment date: 20081110

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBVIE BIOTECHNOLOGY LTD

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20150422

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1126676

Country of ref document: HK